Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Philip Morris International Inc.PM · Entity 2818 | Chief Life Sciences Officer | February 04, 2021 | February 08, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Philip Morris International Inc.
Report date February 04, 2021 · Filed February 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,470 |
Reported balance
After 2021-02-04 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-02-04 · Grant · Acquired 4,250 · Balance 10,470 F1: Restricted Share Units awarded under the Philip Morris International Inc. 2017 Performance Incentive Plan. These Restricted Share Units will vest on February 21, 2024. F2: The average of the high and low price of Philip Morris International Inc. common stock on February 4, 2021. F3: Restricted Share Units. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Share Units awarded under the Philip Morris International Inc. 2017 Performance Incentive Plan. These Restricted Share Units will vest on February 21, 2024.
F2: The average of the high and low price of Philip Morris International Inc. common stock on February 4, 2021.
F3: Restricted Share Units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 04, 2021 Filed Feb 8, 2021 16:11 UTC | Philip Morris International Inc. PM · Entity 2818 | GrantCommon Stock | 4,250 | $81.86 | $347,883.75 |
DisclosureSEC source: 0001182489-21-000011 · edgar.xml · nonDerivative · entry 1 O'Mullane John · CIK 0001776150 · Chief Life Sciences Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,470 F1 · shares: Restricted Share Units awarded under the Philip Morris International Inc. 2017 Performance Incentive Plan. These Restricted Share Units will vest on February 21, 2024. F2 · price: The average of the high and low price of Philip Morris International Inc. common stock on February 4, 2021. F3 · balance_after: Restricted Share Units. Read SEC document |
| February 06, 2020 Filed Feb 10, 2020 16:33 UTC | Philip Morris International Inc. PM · Entity 2818 | GrantCommon Stock | 6,220 | $86.69 | $539,211.80 |
DisclosureSEC source: 0001182489-20-000029 · edgar.xml · nonDerivative · entry 1 O'Mullane John · CIK 0001776150 · Chief Life Sciences Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,220 F1 · shares: Restricted Share Units awarded under the Philip Morris International Inc. 2017 Performance Incentive Plan. F2 · price: The average of the high and low price of Philip Morris International Inc. common stock on February 6, 2020. F3 · balance_after: Restricted Share Units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.